DelveInsight’s Obstructive Sleep Apnea Market Insights report includes a comprehensive understanding of current treatment practices, obstructive sleep apnea emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

 

Key Takeaways from the Obstructive Sleep Apnea Market Report

• As per DelveInsight analysis, the obstructive sleep apnea market size in the 7MM was approximately USD 408 million in 2022.
• According to the assessment done by DelveInsight, the estimated total prevalent obstructive sleep apnea cases in the 7MM were approximately 24 million in 2022. 
• Globally, leading obstructive sleep apnea companies such as Apnimed, Eli Lilly and Company, Therapix Biosciences, Bioprojet Pharma, Axsome Therapeutics/ Jazz Pharmaceuticals and others are developing novel obstructive sleep apnea drugs that can be available in the obstructive sleep apnea market in the coming years.
• The promising obstructive sleep apnea therapies in the pipeline include AD109, Tirzepatide, and others.
• In January 2023, Aculys Pharma initiated a Phase III trial of Pitolisant treating patients with EDS associated with OSA in Japan.

 

Discover which therapies are expected to grab the major obstructive sleep apnea market share @ Obstructive Sleep Apnea Market Research Report

 

Obstructive Sleep Apnea Overview

Obstructive sleep apnea, also known as obstructive sleep apnea-hypopnea, is a sleeping disorder that causes the airflow to stop or drastically decrease while breathing is attempted. It is the most common type of sleep-disordered breathing and is characterized by recurring bouts of upper airway collapse as a person sleeps. Common obstructive sleep apnea symptoms include inexplicable daytime tiredness, restless sleep, and loud snoring. Morning headaches; sleeplessness; difficulty concentrating; and mood changes such as impatience, anxiety, melancholy, and others are less prevalent obstructive sleep apnea symptoms.

 

Obstructive Sleep Apnea Epidemiology Segmentation

• Total Obstructive Sleep Apnea Diagnosed Prevalent Cases
• Obstructive Sleep Apnea Gender-specific Diagnosed Prevalent Cases
• Obstructive Sleep Apnea Age-specific Diagnosed Prevalent Cases
• Obstructive Sleep Apnea Severity-specific Diagnosed Cases

 

Download the report to understand which factors are driving obstructive sleep apnea epidemiology trends @ Obstructive Sleep Apnea Epidemiological Insights

 

Obstructive Sleep Apnea Treatment Market 

Obstructive sleep apnea is often treated with weight loss and exercise, CPAP therapy (the first line of obstructive sleep apnea treatment), bilevel positive airway pressure (BPAP) equipment (if CPAP therapy is ineffective), and surgery. EDS, the most usually related indication, can be treated with PROVIGIL/MODIODAL (modafinil), NUVIGIL (armodafinil), SUNOSI (solriamfetol), Pitolisant, and certain other off-label medications. PROVIGIL (modafinil), which Cephalon introduced in 1999, is used to treat excessive drowsiness caused by narcolepsy, obstructive sleep apnea, and shift work disorder. Provigil is approved for the treatment of EDS associated with narcolepsy in over 30 countries outside the United States, including France, the United Kingdom, Ireland, Italy, and Germany, under several trade names.

 

To know more about obstructive sleep apnea treatment guidelines, visit @ Obstructive Sleep Apnea Treatment Landscape

 

Obstructive Sleep Apnea Therapies and Key Companies

• AD109: Apnimed
• Tirzepatide: Eli Lilly and Company
• AD113: Apnimed
• SUNOSI (Solriamfetol): Axsome Therapeutics/Jazz Pharmaceuticals
• OZAWADE (Pitolisant): Bioprojet Pharma

 

Learn more about the FDA-approved drugs for obstructive sleep apnea @ Drugs for Obstructive Sleep Apnea Treatment

 

Obstructive Sleep Apnea Market Dynamics

The dynamics of the obstructive sleep apnea market are expected to change in the coming years. The tremendous growth of the sleep apnea diagnosis market over the last decade can be linked to the constant advancement of sleep apnea therapy utilization. Moreover, obstructive sleep apnea is poorly understood; implementing programs such as “sleep awareness week” by various organizations and government agencies might boost the diagnosis rate and obstructive sleep apnea treatment.

 

Obstructive Sleep Apnea Drugs Uptake

AD109, a lead product of Apnimed in Phase III, is a first-in-class, oral pharmaceutical combination dosed once daily at bedtime, designed to treat OSA patients across a broad spectrum of disease severity. AD109 combines a selective norepinephrine reuptake inhibitor (NRI), atomoxetine, with a novel NCE selective antimuscarinic, aroxybutynin and has been granted with FTD.

Tirzepatide sponsored by Eli Lilly and Company is a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist. It is in Phase III development for OSA and is also being studied for adults with obesity or overweight with weight-related comorbidity, heart failure with preserved ejection fraction (HFpEF), and nonalcoholic steatohepatitis (NASH).

 

Scope of the Obstructive Sleep Apnea Market Report

• Therapeutic Assessment: Obstructive Sleep Apnea current marketed and emerging therapies
• Obstructive Sleep Apnea Market Dynamics: Attribute Analysis of Emerging Obstructive Sleep Apnea Drugs 
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL’s Views, Analyst’s Views, Obstructive Sleep Apnea Market Access and Reimbursement

 

Discover more about obstructive sleep apnea drugs in development @ Obstructive Sleep Apnea Clinical Trials

 

Table of Content

1. Key Insights

2. Report Introduction

3. Obstructive Sleep Apnea Market Overview at a Glance

4. Executive Summary of Obstructive Sleep Apnea

5. Epidemiology and Market Methodology

6. Key Events

7. Disease Background and Overview Obstructive Sleep Apnea

8. Epidemiology and Patient Population of Obstructive Sleep Apnea

9. Patient Journey

10. Obstructive Sleep Apnea Marketed drugs

11. Obstructive Sleep Apnea Emerging Drugs

12. Obstructive Sleep Apnea: Seven Major Market Analysis

13. Obstructive Sleep Apnea Unmet Needs

14. Obstructive Sleep Apnea SWOT Analysis

15. Key Opinion Leaders’ Views

16. Obstructive Sleep Apnea Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services